Combotope Therapeutics

Combotope Therapeutics is a preclinical-stage biotech leveraging its proprietary SMART-Phage™ platform to discover antibodies against a universal cancer target: Tn/STn glycoproteins. The technology enables the generation of high-affinity, tumor-specific binders against a vast array of established cancer-associated protein targets (CD markers, receptors, mucins), which can be formatted into various modalities like ADCs, bispecifics, and CAR-Ts. The company operates a partnership-driven business model, offering access to its platform and novel antibody candidates to therapeutic developers. With a strong scientific foundation evidenced by a recent publication in Nature Chemical Biology and an experienced founding team, Combotope is positioning itself as a key enabler of next-generation, precision oncology therapeutics.

SMART-Phage™ Antibody Discovery Platform for generating antibodies that specifically bind tumor-specific Tn/STn glycoprotein epitopes, enabling true tumor specificity by targeting the combined glycan-protein structure.

Competition exists from other companies targeting tumor-associated carbohydrates (e.g., GlycoEra, Palleon Pharmaceuticals) and those developing platform technologies for antibody discovery. Combotope's differentiation lies in its specific focus on the Tn/STn glycopeptide epitope and its SMART-Phage™ platform designed to exploit this target, claiming an 'untouched IP space.'